The Phase 2 ELOQUENT-3 trial randomised 117 patients with relapsed and refractory multiple myeloma
to treatment with EPd or Pd in 28-day cycles until disease progression or unacceptable toxicity.
is an incurable blood cancer that starts in the bone marrow and is characterized by an excess proliferation of plasma cells.1 Approximately 6,313 new patients were expected to be diagnosed with multiple myeloma
and approximately 4,338 people were expected to die from the disease in Japan in 2018.2 Globally, it was estimated that 160,000 people were diagnosed and 106,000 died from the disease in 2018.3 While some patients with multiple myeloma
have no symptoms at all, most patients are diagnosed due to symptoms which can include bone problems, low blood counts, calcium elevation, kidney problems or infections.4
For their part, the Tisch researchers said they are also assessing selinexor for treatment of multiple myeloma
in combination with other approved multiple myeloma
drugs, as well for treatment of other cancers such lymphoma and ovarian cancer.
The approval for the REVLIMID triplet (RVd) was supported by data from SWOG S07773, a phase 3 trial evaluating the triplet combination, RVd, in adult patients with previously untreated multiple myeloma
gender and stages of multiple myeloma
. Satisfactory data was taken in correspondence to gender and age.
Extraosseous involvement of multiple myeloma
has increased in the last several decades, possibly due in part to improved imaging detection and increased patient survival.
In a separate analysis, the researchers examined the 16 cases of multiple myeloma
diagnosed between September 12, 2001, and July 1, 2017, among all white, male WTC-exposed FDNY firefighters.
The study analysed the impact of IL-18 on 152 patients with multiple myeloma
and found strong evidence that high levels of the molecule were associated with poorer survival.
A definite diagnosis of Ig G/[lambda] multiple myeloma
"Up to 40 percent of patients remain untreated for the prevention of bone complications, and the percentage is highest among patients with renal impairment at the time of diagnosis," said Noopur Raje, M.D., director, Center for Multiple Myeloma
, Massachusetts General Hospital Cancer Center, Boston.
Takeda Pharmaceutical Company Limited announced that data from two Phase 1/2 clinical trials evaluating NINLARO (ixazomib) in patients with newly diagnosed multiple myeloma
will be presented during sessions at the 2017 European Hematology Association (EHA) annual meeting.
remains an all but incurable terminally differentiated B cell malignancy.